TNFSF13B and renal cell carcinoma: To evaluate this possibility, we treated HOOK1‐decreasing cells with different concentrations of belimumab, an FDA approved antibody against TNFSF13B,[9] to determine whether HOOK1 diminished RCC angiogenesis progression via TNFSF13B.